natgillin/translations-raw huggingface dataset:
These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma possibly persisting for more than 63 days).
Te reakcije so v večini primerov v obliki splošne otekline na mestu injiciranja (ne traja več kot 9 dni) ali kot otipljivi noduli (subkutani granulomi, ki lahko trajajo tudi več kot 63 dni).
These reactions usually disappear or significantly diminish with continued use and may be ameliorated by appropriate treatment with beta2- agonists prior to or following dry powder colistimethate sodium inhalation.
Te reakcije običajno izginejo ali se značilno zmanjšajo z nadaljevanjem uporabe, mogoče pa jih je tudi ublažiti z ustreznim zdravljenjem z agonisti beta2 pred inhaliranjem suhega praška z natrijevim kolistimetatom ali po njem.
These reactions usually regress within one week.
Reakcija navadno izgine v enem tednu.
These reactions varied from isolated skin reactions to serious systemic reactions (i.e. anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex.
Reakcije so se razlikovale od posameznih primerov kožnih reakcij do resnih sistemskih reakcij (t.j. anafilaksija, anafilaktični šok) in so se pojavile tudi pri bolnikih, ki pred tem še niso prejeli sugamadeksa.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4
Neželeni učinki so bili opisani po merilih NCI Common Toxicity Criteria (3. stopnja = S3, 3.–4. stopnja
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4) and the COSTART and the MedDRA terms.
Neţelene učinke so opisali po merilih NCI Common Toxicity Criteria (3. stopnja = S 3, 3.– 4. stopnja = S3/4, 4. stopnja = S4) in z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4) and the COSTART and the MedRA terms.
Neţelene učinke so opisali po splošnih merilih NCI Common Toxicity Criteria (3. stopnja = S 3, 3.– 4. stopnja = S3/4, 4. stopnja = S4) in z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
3.-4. stopnja = S3/4, 4. stopnja = S4) in z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Neželene učinke so opisali po merilih NCI Common Toxicity Criteria (3. stopnja = S 3, 3.– 4. stopnja = S 3/4, 4. stopnja = S 4) z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Neželene učinke so opisali po splošnih merilih NCI Common Toxicity Criteria (3. stopnja = S 3, 3.– 4. stopnja = S 3/4, 4. stopnja = S 4) z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Neželeni učinki so bili opisani po merilih NCI Common Toxicity Criteria (3. stopnja = S3, 3.– 4. stopnja = S3/4, 4. stopnja = S4) z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Neželeni učinki so bili opisani po merilih NCI Common Toxicity Criteria (3. stopnja = S3, 3.– stopnja = S3/4, 4. stopnja = S4) in z izrazi COSTART in MedDRA.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Neželeni učinki so bili opisani po merilih NCI Common Toxicity Criteria (3. stopnja = S3, 3.– stopnja = S3/4, 4. stopnja = S4) z izrazi COSTART in MedDRA.
These reactions were generally observed on the day of infusion, but acute hypersensitivity reactions may also occur on the day after dosing.
Te reakcije so na splošno opažali na dan infundiranja, toda akutne preobčutljivostne reakcije se lahko pojavijo tudi na dan po uporabi.
These reactions were less commonly observed in antibody-negative patients (4 %) compared with antibody-positive patients (13 %), with a greater incidence in those with higher titre antibodies.
Te reakcije so bile manj pogoste pri bolnikih brez titrov protiteles (4 %) v primerjavi z bolniki s prisotnimi protitelesi (13 %), z večjo incidenco pri tistih z višjim titrom protiteles.
These reactions were more common in patients with baseline eGFR ≥ 30 and < 60 mL/min/1.73m2 (18.5% dapagliflozin 10 mg vs 9.3% placebo).
Te reakcije so bile pogostejše pri bolnikih z izhodiščno ocenjeno hitrostjo glomerularne filtracije [eGFR] ≥ 30 in < 60 ml/min/1,73 m2 (18,5 % z 10 mg dapagliflozina in 9,3 % s placebom).
These reactions were usually Grade 1 or 2 (0 – 5 episodes of vomiting in 24 hours) and were either self-limiting or readily controlled with standard anti-emetic therapy.
Oba učinka sta bila ponavadi 1. ali 2. stopnje (od 0 do 5 epizod bruhanja v 24 urah) in sta prenehala sama ali pa ju je bilo mogoče hitro obvladati s standardnim antiemetičnim zdravljenjem.
These reactions were usually Grade 1 or 2 (0 – 5 episodes of vomiting in 24 hours) and were either self-limiting or readily controlled with standard anti-emetic therapy.
Ti učinki so bili navadno stopnje 1 ali 2 (0-5 epizod bruhanja v 24 urah) in so izzveneli sami od sebe ali pa jih je bilo mogoče zlahka nadzorovati s standardnim antiemetičnim zdravljenjem.
These reactions were usually resolved spontaneously within 1 to 3 days after onset.
Večina reakcij je spontano izzvenela v 1 do 3 dneh od pojava.
These reactions will usually occur before leaving the doctor’s surgery.
Ti učinki se po navadi pojavijo, še preden zapustite zdravnikovo ordinacijo.
These receptors control blood levels of cholesterol, especially LDL- cholesterol, by removing it from the blood stream.
Ti receptorji uravnavajo ravni holesterola v krvi, predvsem holesterola LDL, tako da jih odstranijo iz krvnega obtoka.
These receptors control blood levels of cholesterol, especially LDL-cholesterol, by removing it from the bloodstream.
Ti receptorji uravnavajo ravni holesterola v krvi, predvsem holesterola LDL, tako da ga odstranijo iz krvnega obtoka.
These reports include visual acuity reduced, blurred vision, photopsia, visual field defect, visual impairment, dry eye, eyelid oedema, blepharospasm, eye pain and eye swelling.
Med drugim so poročali o zmanjšanju ostrine vida, zamegljenem vidu, fotopsiji, okvarah vidnega polja, poslabšanju vida, suhih očeh, edemu veke, blefarospazmu, bolečinah v očeh in otekanju oči.
These represent an evaluation of the adverse reaction data from 870 patients with newly diagnosed Ph+ chronic phase CML or with Ph+ chronic, accelerated, or blast phase CML or Ph+ acute lymphoblastic leukaemia (ALL) resistant or intolerant to prior therapy and who have received at least 1 dose of single-agent bosutinib.
Ti predstavljajo oceno podatkov o neželenih učinkih, zbranih pri 870 bolnikih z novo odkrito Ph+ KML v kronični fazi ali bolnikih s Ph+ KML v kronični, pospešeni ali blastni fazi ali s Ph+ akutno limfoblastno levkemijo (ALL), ki so bili neodzivni ali pa niso prenašali predhodnega zdravljenja; vsi ti bolniki so prejeli vsaj 1 odmerek bosutiniba kot samostojno zdravilo.
These resolve without any treatment.
Ti preidejo brez zdravljenja.
These results are consistent with those observed in patients treated with intravenous tocilizumab.
Ti rezultati so skladni z opaženimi pri bolnikih, zdravljenih z intravenskim tocilizumabom.
These results imply that young animals lack fully developed metabolic pathways enabling them to excrete amprenavir or some critical components of the formulation (e.g. propylene glycol, PEG400).
Dobljeni rezultati kažejo, da se pri mladičih, katerih presnovne poti še niso docela razvite, amprenavir ali nekatere druge sestavine zdravila (npr. propilenglikol, PEG 400) niso mogli izločati.
These results in clinical practice are consistent with the established safety profile in this indication.
Ta opažanja v vsakdanji klinični praksi potrjujejo dokazan varnostni profil za to indikacijo.
These results indicate that ataluren 10-, 10-, 20-mg/kg slows the loss of walking ability in nmDMD patients.
Ti rezultati kažejo, da ataluren v odmerkih 10, 10 in 20 mg/kg upočasni izgubo zmožnosti hoje pri bolnikih z nmDMD.
These results indicate that fewer patients receiving ataluren 10-, 10-, 20-mg/kg worsened in 6MWD over 48 weeks.
Ti rezultati kažejo, da se je razdalja, prehojena v 6 minutah, v 48 tednih poslabšala pri manj bolnikih, ki so prejemali ataluren v odmerkih 10, 10 in 20 mg/kg.
These results indicate that mirabegron enhances urine storage function by stimulating beta 3-adrenoceptors in the bladder.
Ti rezultati kaţejo, da mirabegron s stimulacijo adrenergičnih receptorjev beta 3 v sečnem mehurju izboljša shranjevanje urina.
These results indicate that rasagiline’s therapeutic concentrations are unlikely to cause any clinically significant interference with substrates of these enzymes.
Glede na te rezultate ni verjetno, da bi terapevtske koncentracije razagilina klinično pomembno součinkovale s substrati teh encimov.
These results indicate that Triumeq can be taken with or without food.
Ti rezultati kažejo, da se zdravilo Triumeq lahko jemlje med jedjo ali na tešče.
These results suggest that co-administration of ospemifene with any medicinal products that inhibit both CYP3A4 and CYP2C9 activity (e.g. fluconazole) would be expected to increase the exposure of ospemifene in a similar way.
Ti rezultati kažejo, da je pričakovati, da bo sočasna uporaba ospemifena s katerim koli zdravilom, ki zavira aktivnost CYP3A4 in CYP2C9 (npr. flukonazol), povečala izpostavljenost ospemifenu na podoben način.
These results suggest that some patients who have not responded by week 4 benefit from continued maintenance therapy through week
To kaže, da lahko nadaljnje zdravljenje do 12. tedna koristi nekaterim bolnikom, ki se ne odzovejo do 4. tedna.
These results suggest that some patients who have not responded by Week 4 benefit from continued maintenance therapy through week 12.
To kaže, da lahko nadaljnje zdravljenje do 12. tedna koristi nekaterim bolnikom, ki se ne odzovejo do 4. tedna.
These results support efficacy across the entire duration of treatment and improvement in PANSS and was observed as early as day 4 with significant separation from placebo in the 25 mg and 150 mg Xeplion groups by day 8.
Ti rezultati podpirajo učinkovitost med celotnim trajanjem zdravljenja in vrednosti lestvice PANSS, ki so jo opazili že 4. dan, pri čemer sta se v skupinah, ki sta prejemali 25 in 150 mg zdravila Xeplion, do osmega dneva pomembno razlikovala od placeba.
These results were confirmed in a sensitivity analysis where superficial neovascularisation was evaluated by an independent assessor from blinded photos of patients’ eyes taken before and after Holoclar implantation.
Te rezultate so potrdili v analizi občutljivosti, v kateri je površinsko neovaskularizacijo ocenil neodvisni ocenjevalec na anonimiziranih fotografijah oči bolnikov, narejenih pred implantacijo zdravila Holoclar in po njej.
These samples will be analysed to measure the normal amount of 13C in the carbon dioxide in your breath.
Te vzorce bodo analizirali z namenom, da določijo običajno količino 13C v ogljikovem dioksidu vašega izdihanega zraka.
These samples will be analysed to measure the “normal” amount of carbon-13 content in the carbon dioxide in your breath.
Te vzorce bodo analizirali za določitev "normalne" količine ogljika-13 v ogljikovem dioksidu v izdihanem zraku.
these sedatives/hypnotics and a
navedenimi pomirjevali/uspavali je
These serious side effects are uncommon.
Ti resni neželeni učinki so občasni.
These short periods when premature babies stop breathing are due to the baby’s breathing centres not being fully developed.
Do teh kratkih obdobij, ko nedonošenček preneha dihati, pride zaradi tega, ker njegov dihalni center še ni povsem razvit.
These should be discussed with the child’s doctor at all medical consultations, including those for dose increases and decreases, and at any other time should you be concerned.
O njih se posvetujte z otrokovim zdravnikom ob obisku zdravnika, tudi o neželenih učinkih pri povečanju in zmanjšanju odmerka, in vsakič, ko ste zaskrbljeni.
These should be taken at least 4 hours before or 4 hours after Epclusa; proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole).
Te je treba vzeti vsaj 4 ure pred uporabo zdravila Epclusa ali 4 ure po tem; zaviralce protonske črpalke (kot so omeprazol, lansoprazol, rabeprazol, pantoprazol in esomeprazol).
These should be taken at least 4 hours before or 4 hours after Harvoni; proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole).
Te je treba vzeti vsaj 4 ure pred uporabo zdravila Harvoni ali 4 ure po tem, zaviralci protonske črpalke (kot so omeprazol, lansoprazol, rabeprazol, pantoprazol in esomeprazol).
These show how well your kidneys are working.
Ti snovi kažeta kako dobro vam delujejo ledvice.
These showed a close temporal relationship and positive rechallenge and dechallenge which support a causal relationship between Ganfort / Ganfort PF and bradycardia.
Pri teh so bili ugotovljeni tesna časovna povezava in pozitiven odziv na ponovno uporabo in prenehanje uporabe, kar podpira vzročno povezavo med zdravilom Ganfort/Ganfort PF in bradikardijo.
These side effects are common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people) or have been reported in very few patients.
Ti neželeni učinki so pogosti (lahko se pojavijo pri 1 od 10 bolnikov), občasni (lahko se pojavijo pri 1 od 100 bolnikov) ali pa so o njih poročali le pri manjšem številu bolnikov.
These side effects are common.
Ti neželeni učinki so pogosti.
These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Našteti neželeni učinki so najpogostnejši prvi teden zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
These side effects are mainly seen in patients with Parkinson’s disease.
Ti neželeni učinki se pojavijo predvsem pri bolnikih s Parkinsonovo boleznijo.
These side effects are very common but disappear on their own in most cases.
Ti neželeni učinki so zelo pogosti, ampak v večini primerov izginejo sami od sebe.
These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect.
Ti neželeni učinki lahko postanejo resni, zato je pomembno, da se takoj posvetujete s svojim zdravnikom, če se pojavijo.
These side effects decrease with continued treatment.
Ti neželeni učinki s trajanjem zdravljenja upadajo.
These side effects have happened very rarely with Infanrix hexa as with other vaccines against whooping cough.
Ti neželeni učinki so se pojavili zelo redko pri cepljenju s cepivom Infanrix hexa, kot tudi pri drugih cepivih proti oslovskemu kašlju.
These side effects have happened very rarely with other vaccines against whooping cough.
Ti neželeni učinki so se pojavili zelo redko pri drugih cepivih proti oslovskemu kašlju.
These side effects include:
Med neželene učinke sodijo naslednji:
These side effects may affect your skills when driving or doing anything that requires you to be alert, including operating machinery.
Ti neželeni učinki lahko vplivajo na vaše spretnosti, ko vozite ali delate karkoli kar zahteva vašo pozornost, vključno z upravljanjem s stroji.
These side effects may be more severe when Docetaxel Winthrop is used with other anticancer medicines.
Ti neželeni učinki so lahko še hujši, kadar se zdravilo Docetaxel Winthrop uporablja z drugimi zdravili proti raku.
These side effects may be more severe when Taxotere is used with other anticancer medicines.
Ti neželeni učinki so lahko še hujši, kadar se zdravilo Taxotere uporablja z drugimi zdravili proti raku.
These side effects may occur with Arepanrix.
Ti neželeni učinki se lahko pojavijo tudi pri cepivu Arepanrix.
These side effects may occur with certain frequencies, which are defined as follows:
Do neželenih učinkov lahko pride z določeno pogostostjo, ki je definirana na naslednji način:
These side effects may occur with certain frequencies, which are defined as follows:
Ti neželeni učinki se lahko pojavljajo z določenimi pogostnostmi, ki so opredeljene takole:
These side effects may occur with Focetria.
Ti neželeni učinki se lahko pojavijo po uporabi cepiva Focetria.
These side effects may stop if the drip is given more slowly over a longer period of time.
Ti neželeni učinki se lahko zmanjšajo, če se infundira počasneje v daljšem časovnem obdobju.
These side effects usually disappear within 1-2 days without treatment.
Ti neţeleni učinki običajno izzvenijo v 1–2 dneh brez zdravljenja.
These side effects usually go away quickly without any treatment.
Ti neželeni učinki ponavadi minejo hitro brez kakršnegakoli zdravljenja.
These side effects were also the most common side effects when Opdivo was used together with ipilimumab.
Ti neželeni učinki so bili tudi najpogostejši pri uporabi zdravila Opdivo skupaj z ipilimumabom.
These side effects will be described in the cisplatin patient information leaflet.
Neželeni učinki cisplatina so opisani v njegovih navodilih za uporabo.
These signs are usually transient and generally resolve within 24-48 hours.
Ti znaki so navadno prehodni in na splošno izginejo v 24 do 48 urah.
These signs disappear without further treatment.
Ti znaki izginejo brez zdravljenja.
These signs disappear without further treatment.
Ti znaki izginejo ne da bi jih zdravili.
These signs disappear without further treatment.
Ti znaki izginejo, ne da bi jih zdravili.
These signs disappear without further treatment.
Ti znaki izzvenijo, ne da bi jih zdravili.
These signs may include weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or growths on the skin;
Znaki lahko vključujejo zmanjšanje telesne mase, vročino, pojav otekline (z bolečino ali brez nje), trdovratnega kašlja, zatrdlin ali izrastkov na koži;
These signs typically started during the first month of treatment (about 30% of dogs showed at least one
Ti znaki se tipično začnejo v prvem
These signs will resolve spontaneously following treatment discontinuation,
Znaki bodo spontano prenehali po prenehanju zdravljenja.
These simulations further suggest that comparable serum IgG trough levels can be achieved when the weekly maintenance dose of Hizentra is administered in proportional amounts more frequently than once a week (e.g.
Te simulacije nadalje nakazujejo, da je mogoče doseči primerljive najnižje ravni IgG v serumu z dajanjem tedenskih vzdrževalnih odmerkov zdravila Hizentra v sorazmernih količinah pogosteje kot enkrat na teden (npr.
These skin lesions were associated with vascular proliferation, skin striae and bone lesions.
Te kožne lezije so bile povezane z vaskularno proliferacijo, kožnimi strijami in lezijami kosti..
these sources is to be
e je treba dogovoriti
These studies are looking at the ability of Humenza to trigger the production of antibodies (‘immunogenicity’) against the H1N1 flu strain.
V teh študijah so proučevali sposobnost cepiva Humenza, da sproži nastajanje protiteles („imunogenost“) proti sevu gripe H1N1.
These studies compared dabigatran etexilate (150 mg bid) with warfarin (target INR 2.0-3.0) in patients with acute DVT and/or PE.
V njih so dabigatran eteksilat (150 mg dvakrat na dan) primerjali z varfarinom (ciljni INR 2,0 do 3,0) pri bolnikih z akutno GVT in/ali PE.
These studies compared the effect of adding Zurampic or placebo (a dummy treatment) to patients’ allopurinol treatment.
V teh študijah so primerjali učinek dodajanja zdravila Zurampic ali placeba (zdravila brez zdravilne učinkovine) zdravljenju z alopurinolom.
These studies did not include patients with severe renal impairment or end stage renal disease.
Te študije niso vključevale bolnikov s hudo okvaro ledvic ali končno ledvično odpovedjo.
These studies evaluated the effects of alogliptin on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or pioglitazone, and as add-on therapy to metformin, or a sulphonylurea, or pioglitazone (with or without metformin or a sulphonylurea), or insulin (with or without metformin).
Te študije so vrednotile učinke alogliptina na urejenost glikemije in njegovo varnost v okviru samostojnega zdravljenja, začetnega kombiniranega zdravljenja z metforminom ali s pioglitazonom ter kot dodatka k zdravljenju z metforminom ali s sulfonilsečnino ali pioglitazonom (z metforminom ali s sulfonilsečnino ali brez) ali z insulinom (z metforminom ali brez).
These studies found a substantial reduction in blood levels of LDL- cholesterol (around 60 to 70% more than placebo, and of around 40% more than ezetimibe) from week 10 to week 12 of the study and at the end of 12 weeks.
V teh študijah so ugotovili veliko zmanjšanje ravni holesterola LDL v krvi (za približno 60 do 70 % več kot pri placebu in približno 40 % več kot pri ezetimibu) od 10. tedna do 12. tedna študije in po preteku 12 tednov.
These studies had a similar design through Week 32.
Ti študiji sta bili do 32. tedna podobno oblikovani.
These studies included 3,525 dulaglutide-treated patients, of whom 2,108 were treated with Trulicity 1.5 mg weekly and 1,417 were treated with Trulicity 0.75 mg weekly.
Te študije so vključevale 3525 bolnikov, zdravljenih z dulaglutidom, od katerih je bilo 2108 bolnikov tedensko zdravljenih z zdravilom Trulicity 1,5 mg, 1417 pa jih je bilo tedensko zdravljenih z zdravilom Trulicity 0,75 mg.
These studies indicate that excessive aliskiren exposure (>400-fold higher in 8-day old rats compared with adult rats) and high acute toxicity in juvenile rats are caused by immature MDR1, which suggests that in paediatric patients with immature MDR1, there is a potential for aliskiren overexposure (see sections 4.2, 4.3 and 5.2).
Rezultati teh študij kažejo, da močno povečano izpostavljenost aliskirenu (ki je pri 8 dni starih podganah >400-krat višja kot pri odraslih) in veliko akutno toksičnost pri podganjih mladičih povzroča nezrelost prenašalcev MDR1, kar lahko pomeni, da pri pediatričnih bolnikih z nezrelimi prenašalci MDR1 lahko pride do prevelike izpostavljenosti aliskirenu (glejte poglavja 4.2, 4.3 in 5.2).
These studies looked at levels of hepatitis B virus in the blood after treatment and the reduction in liver damage.
V teh študijah so proučevali raven virusa hepatitisa B v krvi po zdravljenju in zmanjšanje poškodbe jeter.
These studies looked at the effect of adding Avastin to a combination treatment with carboplatin and gemcitabine or to paclitaxel, topotecan, or pegylated liposomal doxorubicin.
V teh študijah so proučevali učinke dodajanja zdravila Avastin kombinaciji karboplatina in gemcitabina ali paklitakselu, topotekanu ali pegiliranemu liposomskemu doksorubicinu.
These studies measured the viral load (the level of HIV in the patient’s blood) after 48 weeks.
Glavno merilo učinkovitosti je bilo virusno breme (raven virusa HIV v krvi bolnikov) po 48 tednih zdravljenja.
These studies showed that almost all mice that had a Plaque Reduction Neutralization Test titre of at least 1:10 were protected from a lethal Japanese encephalitis virus challenge.
Te študije so pokazale, da so bile skoraj vse miši s titrom najmanj 1:10 pri testu Plaque Reduction Neutralization Test zaščitene pred smrtonosno okužbo z virusom japonskega encefalitisa.
These studies showed that when Praluent was given on top of a statin it led to a substantial reduction in blood levels of LDL-cholesterol (between 39 and 62% more than placebo) after 6 months of treatment.
Študije so pokazale, da je zdravilo Praluent, ki so ga dajali v kombinaciji s statinom, po šestih mesecih zdravljenja znatno znižalo ravni holesterola LDL v krvi (za 39 do 62 % bolj kot placebo).